Plaque Psoriasis

After the FDA’s March approval of ixekizumab (Taltz/ Eli Lilly and Company), researchers recently confirmed the psoriasis treatment was beneficial even after 60 weeks.

Biologic therapies, such as tumor necrosis factor (TNF) inhibitors, can potentially mitigate symptoms of depression and insomnia in patients with psoriasis and psoriatic arthritis.

Nearly 50% of Medicare patients taking biologic therapies for moderate-to-severe plaque psoriasis stop treatment within a year, reported a study by the Perelman School of Medicine at the University of Pennsylvania.

Researchers have concluded that there is a small but significant genetic component to the observed connection between high body mass index (BMI) and psoriasis.

A new study has uncovered a potential shared genetic source between psoriasis and obesity, which could also address a connection among psoriasis, type 2 diabetes, and body mass index (BMI).

Patients afflicted with psoriasis have higher odds of developing abdominal aortic aneurysms.

The FDA has approved Inflectra (infliximab-dyyb/Celltrion, Inc), the biosimilar for Remicade (infliximab) for the treatment of patients suffering from serious autoimmune diseases.

Men afflicted with psoriasis are more likely to suffer from erectile dysfunction.

The FDA has approved ixekizumab (Taltz/Eli Lilly) for moderate to severe plaque psoriasis. It is administered by injection.

Researchers have discovered new Lyme disease-causing bacteria, Borrelia mayonii (B. mayonii) in the upper Midwest. Infection may trigger nausea, vomiting, and a more widespread rash, officials say.

Researchers are closing in on a medical treatment for wart-like skin growths know as seborrheic keratosis.

Age matters when it comes to patients’ access to psoriasis treatment.

Biologic drug secukinumab (Cosentyx/Novartis), already FDA approved in January 2015 to treat chronic plaque psoriasis, has now been approved for two new indications: the treatment of active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA).

Graded drug challenges are considered the gold standard for evaluating patients with a low-risk history of a prior adverse drug reactions – like a mild rash or unknown reaction to penicillin as a child.

Seniors who developed the painful rash commonly known as shingles may also be at higher risk of suffering a stroke or heart attack.

Study results suggest that a treatment for psoriasis and multiple sclerosis may induce a dangerous adverse effect, particularly in women. The finding is potentially important, because while treatment with fumaric acid esters has been around for more than 40 years, it is now being used more widely in the United States, Germany, and other areas.

College kids who break out or get hives can, in fact, blame some of their skin problems on heightened levels of psychological stress.

Recent research has discovered evidence potentially supporting a parent-of-origin effect in psoriatic disease.

It is generally well-understood that smoking cigarettes exacerbates symptoms of psoriasis. But recent study results clarify and strengthen the link between smoking and the development of psoriatic lesions.

When I first started seeing patients on my own, I would get annoyed when patients came in with printouts from WebMD, Health.com, or the dreaded Wikipedia.

The healthcare technology company Philips has launched BlueControl 2.0, a device created to treat patients afflicted with psoriasis.

A topical foam product combining calcipotriene and betamethasone dipropionate has been approved for the treatment of plaque psoriasis in adults age 18 and older.

Researchers report that tailored, computer-based training and interventions can increase the effectiveness of health promotion programs for many workplaces.

Psoriasis patients are susceptible to artery inflammation, increasing their risk for cardiovascular disease.

A German cohort study in Archives of Dermatological Research found that antipsoriatic drugs for treatment of moderate-to-severe psoriasis are generally safe over the long-term.

Treating moderate to severe plaque psoriasis is certainly no picnic for patients' pockets.

Individuals afflicted with psoriasis and psoriatic arthritis are also at higher risk for new-onset migraines.

Half of the patients with psoriatic arthritis enrolled in a trial of etanercept continued responding to the medication and complying with treatment guidelines for more than 5 years.

Researchers found that adding kunzea oil to topical psoriasis treatments with liquor carbonis detergens (LCD) and salicylic acid did not improve the irritating skin condition.

Patients with plaque psoriasis and psoriatic arthritis have seen their treatment options increase in recent years. Thanks to more research on the topic they could see even more options in the years to come.